高级搜索
杨钧媛, 蔡红兵. 宫颈癌免疫治疗的耐药机制及应对措施[J]. 肿瘤防治研究, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162
引用本文: 杨钧媛, 蔡红兵. 宫颈癌免疫治疗的耐药机制及应对措施[J]. 肿瘤防治研究, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162
YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162
Citation: YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162

宫颈癌免疫治疗的耐药机制及应对措施

Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer

  • 摘要: 宫颈癌严重威胁全球女性的生命健康,晚期宫颈癌治疗手段有限,5年生存率不到20%,是妇科肿瘤的巨大挑战。免疫治疗是晚期宫颈癌患者的重要治疗手段之一,包括免疫检查点抑制剂、治疗性疫苗和过继性T细胞免疫疗法等,但免疫治疗耐药性使部分患者无应答而效果不佳。因此,迫切需要深入研究和探讨免疫耐药的机制从而改善耐药,现归纳总结了近年有关宫颈癌中免疫耐药机制的相关研究,主要分为肿瘤内在因素和外在免疫环境改变等因素,并介绍针对免疫耐药提出的应对措施及进展。

     

    Abstract: Cervical cancer has become a serious threat to women's health worldwide, advanced cervical cancer has limited treatment options. 5-year survival rate is less than 20%, which is a huge challenge for the gynecologic oncology community. Immunotherapy is one of the important treatment for patients with advanced cervical cancer. including immune checkpoint inhibitors, therapeutic vaccines, and periprocedural T-cell immunotherapy, etc. However, immunotherapy resistance makes some patients non-responsive and ineffective. Therefore, there is an urgent need to study and explore the mechanism of immune resistance to improve drug resistance. The present review summarizes the relevant studies on the mechanism of immune resistance in cervical cancer in recent years, mainly divided into factors such as intrinsic tumor and altered external immune environment, and introduces the countermeasures and progresses proposed for immune resistance.

     

/

返回文章
返回